Plain-English translation of NCT05515315 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a treatment approach for people with advanced esophageal squamous cell carcinoma (a common type of esophageal cancer) that cannot be surgically removed. The study combines a new immunotherapy drug called with chemotherapy, followed by radiation and additional chemotherapy. Researchers want to see if this combination approach can help shrink tumors and improve outcomes for patients.
Currently, the standard treatment for this type of advanced esophageal cancer involves chemotherapy and radiation. This trial exists to see whether adding this new immunotherapy medication might work better by helping the body's immune system fight the cancer more effectively.
You likely qualify if…
You likely don't qualify if…
You would receive the new immunotherapy medication combined with chemotherapy as an initial treatment to try to shrink the tumor. After that, you would receive radiation therapy combined with more chemotherapy. Throughout the study, you would have regular hospital or clinic visits for treatment, blood tests, and imaging scans to monitor how the cancer is responding. The study involves researchers tracking your health and how well the treatment works over several months.
AI-generated summary from trial data · Jul 1, 2026 · Not medical advice
China